Evidence map›Paper›PMID 32620105›Full record

ArticleMicrobial cell factories2020

A programmable CRISPR/Cas9-based phage defense system for Escherichia coli BL21(DE3).

Li Liu, Dongdong Zhao, Lijun Ye, Tao Zhan, Bin Xiong, Muzi Hu, Changhao Bi, Xueli Zhang

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. D-CAPS: an efficient CRISPR-Cas9-based phage defense system forActa biochimica et biophysica Sinica · 2025
    Article
  5. Antimicrobial Activity of Nano-GeOInternational journal of molecular sciences · 2024
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Li LiuUniversity of Sciences and Technology of China, Hefei, 230026, P R China.
Dongdong ZhaoTianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, 300308, P R China.
Lijun YeTianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, 300308, P R China.
Tao ZhanTianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, 300308, P R China.
Bin XiongTianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, 300308, P R China.
Muzi HuTianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, 300308, P R China.
Changhao BiTianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, 300308, P R China. bi_ch@tib.cas.cn.ORCID http://orcid.org/0000-0002-1940-8511
Xueli ZhangTianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, 300308, P R China. zhang_xl@tib.cas.cn.
Chinese Academy of Sciences · CNUniversity of Science and Technology of China · CN

Funding

Key Research Program of the Chinese Academy of Science KFZD-SW-215National Natural Science Foundation of China 31522002National Natural Science Foundation of China 31861143019Tianjin Science Project 14ZCZDSY00157
6 · The paper itself

Abstract

Escherichia coli BL21 is arguably the most popular host for industrial production of proteins, and industrial fermentations are often plagued by phage infections. The CRISPR/Cas system is guided by a gRNA to cleave a specific DNA cassette, which can be developed into a highly efficient programable phage defense system. In this work, we constructed a CRISPR/Cas system targeting multiple positions on the genome of T7 phage and found that the system increased the BL21's defense ability against phage infection. Furthermore, the targeted loci on phage genome played a critical role. For better control of expression of CRISPR/Cas9, various modes were tested, and the OD of the optimized strain BL21(pT7cas9, pT7-3gRNA, prfp) after 4 h of phage infection was significantly improved, reaching 2.0, which was similar to the control culture without phage infection. Although at later time points, the defensive ability of CRISPR/Cas9 systems were not as obvious as that at early time points. The viable cell count of the engineered strain in the presence of phage was only one order of magnitude lower than that of the strain with no infection, which further demonstrated the effectiveness of the CRISPR/Cas9 phage defense system. Finally, the engineered BL21 strain under phage attack expressed RFP protein at about 60% of the un-infected control, which was significantly higher than the parent BL21. In this work, we successfully constructed a programable CRISPR/Cas9 system to increase the ability of E. coli BL21's to defend against phage infection, and created a resistant protein expression host. This work provides a simple and feasible strategy for protecting industrial E. coli strains against phage infection.

Indexed as

BacteriophagesCRISPR-Cas SystemsEscherichia coliGenome, ViralIndustrial MicrobiologyMicroorganisms, Genetically-ModifiedCRISPR/Cas9E. coli BL21Phage

Identifiers

PMID32620105
PMCPMC7332536
OpenAlexW3039490842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.